ClinicalTrials.gg

Program

Teverelix DP

Also written as “Teverelix DP 180 mg”.

Its studies are mostly in Endometriosis · Prostatic Hyperplasia · Prostatic Diseases, led by Antev.

Furthest: phase 2, since Feb 24, 20263 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Antev33 open or runningphase 2since Feb 24, 2026Feb 24, 2026Sep 2027phase 2 · NCT07457164

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2026First study: phase 2 study in Prostatic DiseasesFirst studyNCT07457164 · 40 planned
  2. Jul 15, 2026Phase 2 study in Prostatic HyperplasiaNCT07733934 · 126 planned
  3. Aug 19, 2026Phase 2 study in EndometriosisNCT07914062 · 84 planned

Ahead

  1. Sep 2027Primary completion: phase 2 study in Prostatic DiseasesNCT07457164
  2. May 2028Primary completion: phase 2 study in Prostatic HyperplasiaNCT07733934
  3. Dec 2029Primary completion: phase 2 study in EndometriosisNCT07914062

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07914062Endometriosis2Not yet recruitingDec 202984
NCT07733934Prostatic Hyperplasia2Not yet recruitingMay 2028126
NCT07457164Prostatic Diseases2Not yet recruitingSep 202740

How it is read

Names in the registry

  • “Teverelix DP”, 5 entries
  • “Teverelix DP 180 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.